Quantcast

Latest Cambridge Antibody Technology Stories

2009-08-10 08:00:00

GAITHERSBURG, Md., Aug. 10 /PRNewswire/ -- MedImmune today announced that it has advanced three oncology antibody programs into Phase 1 clinical development within the past six months. All three of the antibody candidates will target a variety of advanced solid tumors, but via different pathways. "Cancer research has long been a priority focus area at MedImmune and we are proud of the organization's hard work to achieve first-time-in-human-status for all three candidates," said Laurence...

2009-07-15 07:00:00

EXTON, Pa., July 15 /PRNewswire/ -- Morphotek((R)), Inc., a subsidiary of Eisai Corporation of North America, and Cancer Innovations, Inc. (CII), a privately held biotechnology company specializing in the development of oncology products, today announced that they have entered into an evaluation and option agreement in which Morphotek will evaluate monoclonal antibodies targeting certain tumor-associated proteins. The agreement with CII provides Morphotek access to several of CII's...

2009-07-07 07:30:00

SOUTH SAN FRANCISCO, Calif., July 7 /PRNewswire/ -- Catalyst Biosciences, Inc. today announced the signing of an exclusive worldwide research and license agreement with MedImmune, the global biologics unit of AstraZeneca plc, to develop novel engineered proteases that specifically degrade or modulate two targets, one of which will address inflammatory and autoimmune diseases. Catalyst will receive undisclosed upfront licensing fees, full-time employee (FTE) support and milestone payments...

2009-07-01 07:30:00

EXTON, Penn., July 1 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic monoclonal antibodies for the potential treatment of various forms of cancer and infectious disease. Under the terms of the agreement, Synageva will use its proprietary Synageva Expression Platform (SEP(TM)) technology and its expertise to produce and develop a...

2009-04-02 06:00:00

OSLO, Norway, April 2 /PRNewswire/ -- The human antibody company, Affitech AS announced today that the European Patent Office has granted an European patent on the use of phagemid particles having an antibody-coliphage pIII fusion protein, to identify tumor associated antigens on cells by negative selection. The new patent (EP 1065271) is part of the "Breitling" family of patents, originally filed by the German Cancer Research Centre, (Heidelberg, Germany), which is exclusively licensed to...

2009-03-04 05:22:00

COPENHAGEN and OSLO, March 4 /PRNewswire/ -- Pharmexa A/S and Affitech AS announced today that they have entered into a conditional agreement to merge the two companies by means of a share for share acquisition by Pharmexa A/S of the private Norwegian company, Affitech AS. The purpose of the merger is to transform Pharmexa from a cancer and infectious disease vaccine business into a company focused on the research and development of human antibody therapeutic drugs. Under the terms...

2009-02-02 05:00:00

- Delivery of 20,000 doses of ABthrax will bring at least $150 million in revenue to HGS - ROCKVILLE, Md., Feb. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that it has begun delivery of 20,000 doses of its human monoclonal antibody drug ABthrax(TM) (raxibacumab) to the U.S. Strategic National Stockpile for use in the treatment of inhalation anthrax. (Photo: http://www.newscom.com/cgi-bin/prnh/20090202/PH65324 ) (Logo:...

2008-12-16 08:00:00

BURLINGAME, Calif., Dec. 16 /PRNewswire/ -- Epitomics, Inc., the world's sole provider of humanized rabbit monoclonal antibodies for therapeutic use, today announced the appointment of Zhiqiang An, Ph.D. as Chief Scientific Officer. Dr. An comes to Epitomics from Merck Research Laboratories, where he was Director of Biologics Research. He has over 12 years of experience in drug discovery and development in the biotech and pharmaceutical industries, focusing on therapeutic antibody discovery,...

2008-11-13 09:00:37

GAITHERSBURG, Md., Nov. 13 /PRNewswire/ -- MedImmune today announced the appointment of Tony Zook as its president. Previously, he had been heading the company on an interim basis. MedImmune is the wholly owned biologics business for AstraZeneca PLC. In addition to MedImmune, Mr. Zook is also responsible for AstraZeneca's U.S. and Canadian businesses, as well as AstraZeneca's Global Marketing organization. "I am pleased to continue working with the leadership team here at MedImmune to...

2008-10-31 12:00:32

Genaera, a biopharmaceutical company, has reported that its development partner MedImmune presented interim Phase IIa data on MEDI-528, its monoclonal antibody targeting interleukin-9 in adults with mild, persistent asthma. MedImmune reported the absence of serious, dose-limiting adverse events in the study and concluded that the data also demonstrated an acceptable safety profile for multiple subcutaneous doses of MEDI-528. Interleukin-9 (IL-9) is one of at least 29 naturally occurring...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.